Tenderwize
Wróć do wyszukiwania

Open house Nilotinib discount agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 04, 2027 · 129 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nilotinib, ATC L01EA03 (ausgeschlossen Nilotinib dispergiert in Apfelmus, es sei denn, der Hersteller genießt hierfür Patentschutz)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or volume data; actual discounts and market share impact unknown.

Open-house agreements automatically terminate if a competitive discount contract takes effect for the same substance.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Pharmaceutical companies can enter into non-exclusive discount agreements with AOK Bayern for Nilotinib (ATC L01EA03).
  • Exclusion: Nilotinib dispersed in applesauce unless the manufacturer holds patent protection.
Pokaż pełne podsumowanie

This is an open-house model (not a competitive tender) by AOK Bayern for non-exclusive discount agreements on Nilotinib (ATC L01EA03). Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and a signed contract along with an annex listing the medicines. The agreement runs from 01.03.2025 to 28.02.2027, with possible termination with one month's notice. The open-house model is not subject to procurement law; the form is used only due to lack of a dedicated form. No estimated value is provided.

Ryzyka

No estimated value or volume data; actual discounts and market share impact unknown.

Open-house agreements automatically terminate if a competitive discount contract takes effect for the same substance.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company.
  • Proof of authorization to sign (commercial register extract or power of attorney).

Administrative

  • Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house Nilotinib discount agreements

Non-exclusive discount agreements for Nilotinib (ATC L01EA03), excluding Nilotinib dispersed in applesauce unless patent-protected. All interested pharmaceutical companies meeting eligibility can join. The contract is standard and non-negotiable.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Feb 2025 - Feb 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jan 05, 2027

Szczegóły zamówienia

Data publikacji
21 Jan 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
44907-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30